<DOC>
	<DOCNO>NCT00306150</DOCNO>
	<brief_summary>The purpose study ass aprotinin ( BAYA0128 ) , give intravenously surgery , safe help reduce need blood transfusion bladder surgery .</brief_summary>
	<brief_title>Efficacy Safety Aprotinin Transfusion Requirements Patients Undergoing Radical Total Cystectomy</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Postoperative Hemorrhage</mesh_term>
	<mesh_term>Aprotinin</mesh_term>
	<criteria>Subjects 18 year age old Subjects require elective radical total cystectomy bladder cancer Documented , sign , date informed consent obtain prior study specific procedure perform Subjects previous exposure aprotinin last 6 month know suspected allergy aprotinin Subjects sepsis undergo laparoscopic surgery Subjects impair renal function ( serum creatinine &gt; 2.5 mg/dL 221 micromoles/liter ) Subjects history bleed diathesis , deep vein thrombosis pulmonary embolism know coagulation factor deficiency . Based investigator 's opinion active significant medical illness subject may Subjects refuse receive allogenic blood product whose preoperative red blood cell volume low blood transfusion would likely give perioperatively ( preoperative hematocrit &lt; 24 % hemoglobin &lt; 8 g/dl ) Subjects participated investigational drug study within past 30 day Subjects pregnant breastfeed woman childbearing potential possibility pregnancy exclude negative pregnancy test use reliable method contraception Planned use antifibrinolytic agent , e.g . aminocaproic acid tranexamic acid Subjects chronic anticoagulant treatment warfarin temporarily discontinue surgical procedure ( per local practice )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prevention blood loss</keyword>
	<keyword>Blood Loss , Surgical</keyword>
	<keyword>Blood Loss , Postoperative</keyword>
</DOC>